MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.93M | 8.31M | 8.53M | 7.53M | 8.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.93M | 8.31M | 8.53M | 7.53M | 8.60M |
| Cost of Revenue | 5.21M | 6.46M | 6.10M | 4.62M | 6.60M |
| Gross Profit | 2.73M | 1.85M | 2.44M | 2.91M | 2.00M |
| SG&A Expenses | 3.13M | 3.27M | 5.18M | 3.28M | 3.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 256.80K | 137.20K | -56.40K | -115.70K | 117.90K |
| Total Operating Expenses | 8.63M | 9.90M | 11.25M | 7.84M | 9.85M |
| Operating Income | -693.60K | -1.59M | -2.72M | -305.90K | -1.25M |
| Income Before Tax | -1.41M | -1.56M | -2.72M | -269.70K | -1.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.41M | -1.56M | -2.72M | -269.70K | -1.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.41M | -1.56M | -2.72M | -269.70K | -1.23M |
| EBIT | -693.60K | -1.59M | -2.72M | -305.90K | -1.25M |
| EBITDA | -416.00K | -1.29M | -2.42M | -16.00K | -893.00K |
| EPS Basic | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 421.70M | 420.76M | 415.35M | 415.12M | 411.83M |
| Average Diluted Shares Outstanding | 421.70M | 420.76M | 415.35M | 415.12M | 411.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |